![The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma. - ppt download The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma. - ppt download](https://slideplayer.com/10734826/37/images/slide_1.jpg)
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma. - ppt download
![The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma. - ppt download The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma. - ppt download](https://slideplayer.com/slide/14444678/90/images/5/Outcome+according+to+the+revised+International+Prognostic+Index+%28R-IPI%29..jpg)
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma. - ppt download
![Table 1 from The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. | Semantic Scholar Table 1 from The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0ce5e3433e7e5c0a7252094d6a23f65336327517/2-Table1-1.png)
Table 1 from The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. | Semantic Scholar
A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent | PLOS ONE
![Prognostic impact of MYD88 mutation, proliferative index and cell origin in diffuse large B cell lymphoma | Hematology, Transfusion and Cell Therapy Prognostic impact of MYD88 mutation, proliferative index and cell origin in diffuse large B cell lymphoma | Hematology, Transfusion and Cell Therapy](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S2531137918301251:gr3.jpeg?xkr=ue/ImdikoIMrsJoerZ+w92xcqUtYYCc6yiYRjTD2AR3zJSEmH4GGT8A27de8H5QqAdccHlDwud9PYwTAyLTEDp34QzRYqxzmI0h/F8jXzTa1gIwpb8jvYBldrb2fqxdW1oMscryv/BU3Zg2qtH6rviTzFTY8/S1qsFciQZXmuRmtoYSJ6JjW1CZrMXMjepNMgo2ximhO7TU/bqEl+5T8fq1An+m31RKnrKGzJYjmNhuG8e0a5MvloXffp8WBcui6UrMZV+2ShG+vpLNeR+zTXb9tCEW+CKljxr050Z0TdlUx+q7l3qcA4b/qJ5xp+RGK)
Prognostic impact of MYD88 mutation, proliferative index and cell origin in diffuse large B cell lymphoma | Hematology, Transfusion and Cell Therapy
Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14 | PLOS ONE
![Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma - Maurer - 2021 - American Journal of Hematology - Wiley Online Library Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma - Maurer - 2021 - American Journal of Hematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/55590ce0-5280-4f9f-9092-62815b543c03/ajh26149-fig-0002-m.jpg)
Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma - Maurer - 2021 - American Journal of Hematology - Wiley Online Library
![CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP | Journal of Clinical Oncology CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2016/jco.2015.64.34.issue-26/jco.2015.65.6520/20161107/images/medium/jco656520ta1.gif)
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP | Journal of Clinical Oncology
![Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era | BMC Cancer Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era | BMC Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-022-09693-z/MediaObjects/12885_2022_9693_Fig4_HTML.png)
Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era | BMC Cancer
![Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System | JCO Global Oncology Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System | JCO Global Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/go/2022/go.2022.8/go.22.00165/20221105/images/large/go.22.00165t2.jpeg)
Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System | JCO Global Oncology
![Table 2 from The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. | Semantic Scholar Table 2 from The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0ce5e3433e7e5c0a7252094d6a23f65336327517/3-Table2-1.png)
Table 2 from The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. | Semantic Scholar
![Table 1 from An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. | Semantic Scholar Table 1 from An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5835aee9687d11160fd503ad0ecb876e36789aca/3-Table1-1.png)
Table 1 from An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. | Semantic Scholar
![Regarding R-IPI, 12%, 45%, and 43% pertained to the low, intermediate... | Download Scientific Diagram Regarding R-IPI, 12%, 45%, and 43% pertained to the low, intermediate... | Download Scientific Diagram](https://www.researchgate.net/publication/337778741/figure/tbl1/AS:878494040993792@1586460709189/Regarding-R-IPI-12-45-and-43-pertained-to-the-low-intermediate-and-high-risk.png)
Regarding R-IPI, 12%, 45%, and 43% pertained to the low, intermediate... | Download Scientific Diagram
![The international staging system improves the IPI risk stratification in patients with diffuse large B-cell lymphoma treated with R-CHOP | Scientific Reports The international staging system improves the IPI risk stratification in patients with diffuse large B-cell lymphoma treated with R-CHOP | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-017-13254-x/MediaObjects/41598_2017_13254_Fig1_HTML.png)
The international staging system improves the IPI risk stratification in patients with diffuse large B-cell lymphoma treated with R-CHOP | Scientific Reports
![The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP - ScienceDirect The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497120419056-gr4.jpg)
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP - ScienceDirect
![International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI - ScienceDirect International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497120619760-fx1ab.jpg)
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI - ScienceDirect
![Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP). - ScienceDirect Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP). - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497119753828-fx1.jpg)
Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP). - ScienceDirect
A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent | PLOS ONE
![MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. | Semantic Scholar MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/083e8d4c130f77ea03d9c5e63e9a44b1ba076fdf/2-Table1-1.png)
MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. | Semantic Scholar
![Frontiers | The Application of the Lymphoma International Prognostic Index to Predict Venous Thromboembolic Events in Diffuse Large B-Cell Lymphoma Patients Frontiers | The Application of the Lymphoma International Prognostic Index to Predict Venous Thromboembolic Events in Diffuse Large B-Cell Lymphoma Patients](https://www.frontiersin.org/files/Articles/677776/fonc-11-677776-HTML/image_m/fonc-11-677776-t004.jpg)
Frontiers | The Application of the Lymphoma International Prognostic Index to Predict Venous Thromboembolic Events in Diffuse Large B-Cell Lymphoma Patients
![Improving Outcomes and Evaluating Novel Treatment Approaches for Patients With DLBCL or MCL (Transcript) Improving Outcomes and Evaluating Novel Treatment Approaches for Patients With DLBCL or MCL (Transcript)](https://img.medscapestatic.com/article/747/564/Slide6.png)